Pionyr Immunotherapeutics CEO and leadership

Steven James has over 30 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Currently, Mr. James is Chief Executive Officer and director of Pionyr Immunotherapeutics. Previously, he was president and CEO of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Mr. James was president and CEO of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. He serves as a trustee of Middlebridge School in Rhode Island. Mr. James is currently chairman of Antiva Biosciences and Soteria Therapeutics and a director of Allakos Inc and Ventus Therapeutics. He was formerly a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics).

Evan Greger joined Pionyr Immunotherapeutics in June 2018 and has over 20 years of experience in leadership roles in biopharmaceutical companies, with research, process/product development, manufacturing, CMC, and regulatory expertise. Prior to Pionyr, he served as VP, CMC and Process Development for Cell Design Labs / Kite Pharma, where he worked on next-generation CAR T therapy and was the Senior Director, Manufacturing Process Sciences at Juno Therapeutics, where he advanced CAR T therapies into the EU with Celgene and into China with JW Therapeutics. Prior to this role, Mr. Greger was Global Head of Manufacturing Sciences and Technology for Biopharmaceutical Operations with Novartis in Basel, Switzerland. He previously held senior positions with Amgen, where he led Enbrel commercialization, advanced the oncology and biosimilar pipeline, and at Sanofi Pasteur and Alpharma, where he advanced vaccine development and commercialization. Mr. Greger holds an MBA from Seattle University and an MSc from the University of Washington.

Leonard Reyno is a Senior Vice President and Chief Medical Officer at Pionyr Immunotherapeutics.

Monte Montgomery is the Senior Vice President and Chief Financial Officer at Pionyr Immunotherapeutics.

Dr. Alicia Levey joined Pionyr in July of 2019 and leads business development, business operations, portfolio strategy, and program management in addition to managing intellectual property and legal functions. Prior to Pionyr, Dr. Levey served as the Chief Business Officer of Tempest Therapeutics and was a key contributor to establishing the company outside of Inception Sciences and raising $70M in venture funding. Leading up to the spin-out of Tempest, she was VP of Business Development at Inception Sciences, a small molecule drug discovery company formed in collaboration with Versant Ventures, a global venture capital firm focused primarily on early stage investing and biotechnology company creation. Dr. Levey served as a member of the Versant Ventures Investment Team for over 8 years, most recently as an Operating Principal. While at Versant, she was a key contributor to multiple Series A investments (Novira, Audentes, Therachon among others) as well as business development efforts for portfolio companies. Dr. Levey worked as a Consultant, and later a Project Leader in The Boston Consulting Group. While at BCG, she focused primarily on biopharma and global health. Dr. Levey has authored several peer reviewed scientific publications and her inventions are covered in two United States Patents. While at Stanford, she focused on the development of novel protease inhibitors and activity-based probes for diagnostic imaging applications. Dr. Levey earned a Ph.D. in Cancer Biology from the Stanford University School of Medicine.

Steven James has over 30 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Currently, Mr. James is Chief Executive Officer and director of Pionyr Immunotherapeutics. Previously, he was president and CEO of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Mr. James was president and CEO of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. He serves as a trustee of Middlebridge School in Rhode Island. Mr. James is currently chairman of Antiva Biosciences and Soteria Therapeutics and a director of Allakos Inc and Ventus Therapeutics. He was formerly a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics).

Evan Greger joined Pionyr Immunotherapeutics in June 2018 and has over 20 years of experience in leadership roles in biopharmaceutical companies, with research, process/product development, manufacturing, CMC, and regulatory expertise. Prior to Pionyr, he served as VP, CMC and Process Development for Cell Design Labs / Kite Pharma, where he worked on next-generation CAR T therapy and was the Senior Director, Manufacturing Process Sciences at Juno Therapeutics, where he advanced CAR T therapies into the EU with Celgene and into China with JW Therapeutics. Prior to this role, Mr. Greger was Global Head of Manufacturing Sciences and Technology for Biopharmaceutical Operations with Novartis in Basel, Switzerland. He previously held senior positions with Amgen, where he led Enbrel commercialization, advanced the oncology and biosimilar pipeline, and at Sanofi Pasteur and Alpharma, where he advanced vaccine development and commercialization. Mr. Greger holds an MBA from Seattle University and an MSc from the University of Washington.

Leonard Reyno is a Senior Vice President and Chief Medical Officer at Pionyr Immunotherapeutics.

Monte Montgomery is the Senior Vice President and Chief Financial Officer at Pionyr Immunotherapeutics.

Dr. Alicia Levey joined Pionyr in July of 2019 and leads business development, business operations, portfolio strategy, and program management in addition to managing intellectual property and legal functions. Prior to Pionyr, Dr. Levey served as the Chief Business Officer of Tempest Therapeutics and was a key contributor to establishing the company outside of Inception Sciences and raising $70M in venture funding. Leading up to the spin-out of Tempest, she was VP of Business Development at Inception Sciences, a small molecule drug discovery company formed in collaboration with Versant Ventures, a global venture capital firm focused primarily on early stage investing and biotechnology company creation. Dr. Levey served as a member of the Versant Ventures Investment Team for over 8 years, most recently as an Operating Principal. While at Versant, she was a key contributor to multiple Series A investments (Novira, Audentes, Therachon among others) as well as business development efforts for portfolio companies. Dr. Levey worked as a Consultant, and later a Project Leader in The Boston Consulting Group. While at BCG, she focused primarily on biopharma and global health. Dr. Levey has authored several peer reviewed scientific publications and her inventions are covered in two United States Patents. While at Stanford, she focused on the development of novel protease inhibitors and activity-based probes for diagnostic imaging applications. Dr. Levey earned a Ph.D. in Cancer Biology from the Stanford University School of Medicine.

Steven James has over 30 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Currently, Mr. James is Chief Executive Officer and director of Pionyr Immunotherapeutics. Previously, he was president and CEO of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Mr. James was president and CEO of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. He serves as a trustee of Middlebridge School in Rhode Island. Mr. James is currently chairman of Antiva Biosciences and Soteria Therapeutics and a director of Allakos Inc and Ventus Therapeutics. He was formerly a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics).

Evan Greger joined Pionyr Immunotherapeutics in June 2018 and has over 20 years of experience in leadership roles in biopharmaceutical companies, with research, process/product development, manufacturing, CMC, and regulatory expertise. Prior to Pionyr, he served as VP, CMC and Process Development for Cell Design Labs / Kite Pharma, where he worked on next-generation CAR T therapy and was the Senior Director, Manufacturing Process Sciences at Juno Therapeutics, where he advanced CAR T therapies into the EU with Celgene and into China with JW Therapeutics. Prior to this role, Mr. Greger was Global Head of Manufacturing Sciences and Technology for Biopharmaceutical Operations with Novartis in Basel, Switzerland. He previously held senior positions with Amgen, where he led Enbrel commercialization, advanced the oncology and biosimilar pipeline, and at Sanofi Pasteur and Alpharma, where he advanced vaccine development and commercialization. Mr. Greger holds an MBA from Seattle University and an MSc from the University of Washington.